OKT3 therapy for transfusion-associated graft-versus-host disease in a neonate.
Transfusion-associated graft-versus-host disease (TA-GVHD) is a fatal side effect of blood transfusion. The present study describes a case of TA-GVHD in a neonate treated with anti-CD3 monoclonal antibody (OKT3). The patient died of systemic bacterial infection. However, it is suggested that OKT3 suppressed the graft-versus-host reaction due to the improvement in the clinical signs and a change in the human leucocyte antigen (HLA) type on the surface of circulating lymphocytes. A relatively large dose of OKT3 together with steroid pulse therapy and cyclosporin A may be required for the control of TA-GVHD in neonates.
Murakami
T
T
Department of Pediatric Cardiology, Heart Institute of Japan, Tokyo Women's Medical College, Japan.
Seguchi
M
M
Nakazawa
M
M
Momma
K
K
D001424:Bacterial Infections / Q000209:etiology; D017809:Fatal Outcome; D006086:Graft vs Host Disease / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007231:Infant, Newborn; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D011183:Postoperative Complications; D065227:Transfusion Reaction; D014188:Transposition of Great Vessels / Q000150:complications / Q000601:surgery
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3